Company News

Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced the launch of Ryaltris - AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma.

Pfizer Inc that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyxs lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.

Gilead Sciences, Inc announced that in response to the rapid increase in COVID-19 cases in India, the company is providing its voluntary licensing partners with technical assistance, support for the addition of new local manufacturing facilities and the donation of active pharmaceutical ingredient (API) to rapidly scale up production of remdesivir. Remdesivir is approved in India for restricted emergency use for the treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalized with severe disease.

Glenmark  Pharmaceuticals  Limited,  a  research-led,  global  integrated pharmaceutical company, is concluding the final, national phase of its marketing approval application process to enable launch of its innovative nasal spray in 17 countries in the European Union.

Natco Pharma Limited has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients.

LEO Pharma A/S, a global leader in medical dermatology announced that the Committee for Medicinal Products for Human Use  of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization of Adtralza (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.

Zydus Cadila announced that the company has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of  Virafin, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications.

Johnson and Johnson announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson and& Johnson (Janssen).